Age: 73.0
Sex: F
Vaccine: VARZOS, VARZOS, VARZOS
Symptoms: Biopsy gingival, Biopsy site unspecified abnormal, Fungal skin infection, Oral lichen planus
Clinical narrative: This spontaneous report as received from a 73 years old registered nurse concerning on herself. The patient's medical history included high blood pressure, high cholesterol, gastroesophageal reflux (GERD) and allergy and rash to NIASPAN. The patient's medical history included a case of shingles in approximately December 2009 (two years prior to receiving the vaccine). The patient requested to be vaccinated and received on 05-DEC-2011 a vaccination with a dose of ZOSTAVAX (dose, via, lot number and expiration date not reported). Concomitant therapies included NEXIUM, CORGARD, CELEXA, NASONEX, ZETIA, PRAVACHOL, NORVASC and aspirin. The patient stated that after receiving ZOSTAVAX, she began to experience skin and urinary tract infections around the beginning of January 2012 on an unspecified day. Shortly after that time, she began to notice (in approximately 2012) that her gums would bleed when she brushed her teeth on an unspecified date. The patient consulted her primary physician, who sent her for lab work, a consultation with a dermatologist and a consultation with an oral surgeon on unspecified dates. The lab work, along with the dermatologist consultation, revealed that the source of the infections were yeast. The consultation with the oral surgeon revealed, after a gum biopsy, a diagnosis of Lichen planus, an autoimmune disease. All of her treating physicians agreed that she should be put on a tapering dose of Prednisone (manufacturer unknown) to control her symptoms. The patient reported that she was experiencing relief of her symptoms since being placed on the tapering dose of Prednisone on an unspecified date. Additional information has been received from the patient with a history of chickenpox (onset in 1943) and herpes zoster (first outbreak in 1997, the location of herpes zoster was right, lower buttock area). On 05-DEC-2011 the patient received the first dose of ZOSTAVAX (dose, lot number and expiration date not reported) intramuscularly on the right side of hip. On 01-JAN-2012 the patient experienced location of rash/ herpes zoster (HZ) which was in right buttock at panty line, number of lesions: several. The patient also experienced fungal skin infections, urinary tract infection three times and lichen planus oral. The patient was treated with 10 weeks of tx prednisone (ongoing). Biopsies was performed which result not provided. The outcome of events was reported as recovering. On an unknown date of May 2013 the patient experienced herpes zoster. The number of lesions: several (duration: 10-14 days or 2 weeks). The maximum temperature was normal. The pain was reported as 10. Due to very evident prodromal symptoms, the patient was treated with VALTREX 500 mg, orally, dailyx30 days. No specimen collected for polymerase chain reaction (PCR) analysis and other diagnostic tests performed (done back in 1997 at first outbreak). The patient recovered from herpes zoster. Currently, there was none of herpes zoster episode. There was not recent exposure to chickenpox of HZ. Herpes zoster (01-JAN-2012), fungal skin infections, urinary tract infection three times and lichen planus oral were considered to be events of disability and other important medical events. Additional information is not expected.